📣 VC round data is live. Check it out!
- Public Comps
- AptarGroup
AptarGroup Valuation Multiples
Discover revenue and EBITDA valuation multiples for AptarGroup and similar public comparables like Baxter International, Avantor, Stevanato Group, Sotera Health and more.
AptarGroup Overview
About AptarGroup
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
Founded
1992
HQ

Employees
14.0K
Website
Sectors
Financials (LTM)
EV
$9B
Valuation Multiples
Start free trialAptarGroup Financials
AptarGroup reported last 12-month revenue of $4B and EBITDA of $821M.
In the same LTM period, AptarGroup generated $1B in gross profit, $821M in EBITDA, and $374M in net income.
Revenue (LTM)
AptarGroup P&L
In the most recent fiscal year, AptarGroup reported revenue of $4B and EBITDA of $831M.
AptarGroup is profitable as of last fiscal year, with gross margin of 37%, EBITDA margin of 22%, and net margin of 10%.
Financial data powered by Morningstar, Inc.
AptarGroup Stock Performance
AptarGroup has current market cap of $8B, and enterprise value of $9B.
Market Cap Evolution
AptarGroup's stock price is $120.99.
AptarGroup share price decreased by 2.2% in the last 30 days, and by 23.6% in the last year.
AptarGroup has an EPS (earnings per share) of $6.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $8B | -3.3% | -2.2% | -15.8% | -23.6% | $6.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAptarGroup Valuation Multiples
AptarGroup trades at 2.3x EV/Revenue multiple, and 10.8x EV/EBITDA.
EV / Revenue (LTM)
AptarGroup Financial Valuation Multiples
As of May 10, 2026, AptarGroup has market cap of $8B and EV of $9B.
AptarGroup has a P/E ratio of 20.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AptarGroup Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


AptarGroup Margins & Growth Rates
In the most recent fiscal year, AptarGroup reported gross margin of 37%, EBITDA margin of 22%, and net margin of 10%.
AptarGroup Margins
AptarGroup Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
AptarGroup Operational KPIs
AptarGroup's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
AptarGroup Competitors
AptarGroup competitors include Baxter International, Avantor, Stevanato Group, Sotera Health, Fresenius Medical Care, Schott Pharma, Ansell, Haemonetics, Smith & Nephew and Shandong Weigao Blood.
Most AptarGroup public comparables operate across Medical Supplies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.5x | 1.5x | 22.1x | 7.6x | |||
| 1.4x | 1.4x | 66.4x | 8.9x | |||
| 3.9x | 3.8x | 16.1x | 14.7x | |||
| 5.6x | 5.4x | 10.9x | 10.6x | |||
| 1.0x | 1.0x | 5.3x | 5.4x | |||
| 2.4x | 2.4x | 8.4x | 8.7x | |||
| 1.6x | 1.6x | 9.2x | 8.4x | |||
| 2.5x | 2.6x | 10.1x | 8.6x | |||
This data is available for Pro users. Sign up to see all AptarGroup competitors and their valuation data. Start Free Trial | ||||||
AptarGroup M&A Activity
AptarGroup has acquired 7 companies to date.
Last acquisition by AptarGroup was on July 15th 2025. AptarGroup acquired Mod3 Pharma (clinical trial materials manufacturing capabilities unit) for $7M (EV/Revenue multiple of ).
Latest Acquisitions by AptarGroup
| Description | — | Weihai Hengyu Medical Products is a Weihai-based manufacturer of elastomeric stoppers, plungers, and plastic components for syringes and vials used in injectable pharmaceuticals. Operating under Hongyu Medical, the company supplies global pharma firms with ISO-compliant products from its Shandong facilities. | Voluntis is a Boston-headquartered digital therapeutics company founded in 2001 that develops therapeutic digital apps for chronic disease management including diabetes, oncology, and cardiovascular conditions. Its Patient Relationship Management platform supports remote monitoring through connected devices and mobile apps, serving over 600,000 patients via more than 50 programs with pharma partners like Sanofi and Roche. Voluntis holds FDA clearance for apps like Insulia for insulin dosing. | Cohero Health is a New York City-based digital health company founded in 2013 that offers a connected platform for respiratory disease management. The platform includes BreathEasy inhaler sensors and Pocket Spirometer for real-time adherence tracking via iOS and Android apps. Cohero Health partners with pharmaceutical firms like AstraZeneca and serves clinics monitoring asthma and COPD patients with data dashboards for providers. | |
| HQ Country | |||||
| HQ City | — | Weihai | Paris | New York City, NY | |
| Deal Date | 15 Jul 2025 | 28 Jul 2021 | 24 Jun 2021 | 4 Nov 2020 | |
| Valuation | $7M | $96M | $85M | $2M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all AptarGroup acquisitions and their M&A valuation multiples. Start Free Trial | |||||
AptarGroup Investment Activity
AptarGroup has invested in 4 companies to date.
Latest investment by AptarGroup was on December 10th 2023. AptarGroup invested in GoldRain in their $84M Strategic investment round (EV/Revenue multiple of ).
Latest Investments by AptarGroup
| Description | GoldRain is a Chinese supplier of cosmetic packaging components such as hand-operated sprayers, lotion dispensers, perfume atomizers, and vacuum bottles. Its facilities include an in-house mold center, aluminum anodizing plant, and finishing lines for high-volume production. | Sonmol is a Chinese developer of respiratory health products, including nasal care series for maternal, household, and personal use. Shanghai-based Sonmol offers nebulizers, inhalers, and online management apps for chronic conditions like asthma and COPD. The company provides telemedicine consultations and partners with hospitals in Asia. Sonmol debuted its flagship nasal aspirator line in 2015. | PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins. | Propeller Health is a digital therapeutics company providing inhaler sensors and apps for asthma and COPD management. Milwaukee-headquartered, its FDA-cleared platform attaches to rescue inhalers, tracking usage via Bluetooth and delivering insights on triggers and adherence. Acquired by ResMed in 2021, it partners with health systems like Dignity Health. |
| HQ Country | ||||
| HQ City | Yuyao | Shanghai | Jacksonville, FL | Madison, WI |
| Deal Date | 10 Dec 2023 | 22 May 2020 | 3 Sep 2019 | 30 May 2018 |
| Round | Strategic investment | Strategic investment | Strategic investment | Series D |
| Raised | $84M | $3M | $2M | $20M |
| Investors | AptarGroup | AptarGroup | AptarGroup | 3M New Ventures; AptarGroup; Hikma Ventures; Safeguard Scientifics; Social Capital; SR One |
| Valuation | $210M | undisclosed | undisclosed | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all AptarGroup investments and their VC round multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AptarGroup
| When was AptarGroup founded? | AptarGroup was founded in 1992. |
| Where is AptarGroup headquartered? | AptarGroup is headquartered in United States. |
| How many employees does AptarGroup have? | As of today, AptarGroup has over 14K employees. |
| Who is the CEO of AptarGroup? | AptarGroup's CEO is Stephan B. Tanda. |
| Is AptarGroup publicly listed? | Yes, AptarGroup is a public company listed on NYSE. |
| What is the stock symbol of AptarGroup? | AptarGroup trades under ATR ticker. |
| When did AptarGroup go public? | AptarGroup went public in 1993. |
| Who are competitors of AptarGroup? | AptarGroup main competitors include Baxter International, Avantor, Stevanato Group, Sotera Health, Fresenius Medical Care, Schott Pharma, Ansell, Haemonetics, Smith & Nephew, Shandong Weigao Blood. |
| What is the current market cap of AptarGroup? | AptarGroup's current market cap is $8B. |
| What is the current revenue of AptarGroup? | AptarGroup's last 12 months revenue is $4B. |
| What is the current revenue growth of AptarGroup? | AptarGroup revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of AptarGroup? | Current revenue multiple of AptarGroup is 2.3x. |
| Is AptarGroup profitable? | Yes, AptarGroup is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AptarGroup? | AptarGroup's last 12 months EBITDA is $821M. |
| What is AptarGroup's EBITDA margin? | AptarGroup's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of AptarGroup? | Current EBITDA multiple of AptarGroup is 10.8x. |
| What is the current FCF of AptarGroup? | AptarGroup's last 12 months FCF is $372M. |
| What is AptarGroup's FCF margin? | AptarGroup's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of AptarGroup? | Current FCF multiple of AptarGroup is 23.9x. |
| How many companies AptarGroup has acquired to date? | As of May 2026, AptarGroup has acquired 7 companies. |
| What was the largest acquisition by AptarGroup? | $218M acquisition of Mega Airless on 25th January 2016 was the largest M&A AptarGroup has done to date. |
| What companies AptarGroup acquired? | AptarGroup acquired Mega Airless, FusionPKG, Weihai Hengyu Medical Products, Voluntis, Noble, Mod3 Pharma (clinical trial materials manufacturing capabilities unit), and Cohero Health. |
| In how many companies AptarGroup has invested to date? | As of May 2026, AptarGroup has invested in 4 companies. |
| What was the last AptarGroup investment? | On 10th December 2023 AptarGroup invested in GoldRain, participating in a $84M Strategic investment round at $210M valuation. |
| In what companies AptarGroup invested in? | AptarGroup invested in GoldRain, Propeller Health, Sonmol, and PureCycle. |
See public comps similar to AptarGroup
Lists including AptarGroup
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


